Orano Med, a pioneer in radioligand therapies in oncology, inaugurated the expansion of its R&D Center located in Plano, Texas (USA).

MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) and intended for the treatment of ovarian cancer, is nominated for development under strategic partnership with Orano Med The oral ...

Niger’s military-led government completed the nationalization of SOMAIR, a major uranium mining venture previously operated ...

Niger’s government says it will nationalize the Somaïr uranium venture operated by French company Orano over allegations that it took a disproportionate share of the uranium produced at the ...

Updated Results from the Ongoing Phase 1/2a Study of MP0533, a Tetra-Specific Designed Ankyrin Repeat Protein (DARPin; CD33 x CD123 x CD70 x CD3), in Patients with Relapsed/Refractory AML or MDS/AML ...

New 40-person office in Oak Ridge leads the continuing development of Orano's planned multibillion-dollar uranium enrichment ...

Orano Med, a subsidiary of the Orano Group, is a clinical-stage biotechnology company which develops a new generation of targeted therapies against cancer using the unique properties of lead-212 ...

About Orano Med SAS Orano Med, a subsidiary of the Orano Group, is a clinical-stage biotechnology company which develops a new generation of targeted therapies against cancer using the unique ...

New agreement enables both companies to fuel a broad and innovative pipeline of 212Pb-Radio-DARPin candidates, bringing the total number of programs up to tenExpanded partnership highlights the ...